# US 2016/0243204 A1 · Candidates against infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0243204 A1
- Document ID: US20160243204A1
- Status: Published application
- Kind: A1
- Application number: 14/964,481
- Filed: 2015-12-09
- Published: 2016-08-25
- Earliest claimed: 2006-08-28
- Assignees: Omnio Healer AB
- Applicants: Omnio Healer AB
- Inventors: Tor NY; Jinan LI; Yongzhi GUO
- Web page: https://patentgrep.com/patent/US20160243204A1

## CPC

- A61K 38/484: {Plasmin (3.4.21.7)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/5088: {of vertebrates}
- C12Y 304/21007: Plasmin (3.4.21.7), i.e. fibrinolysin
- G01N 2333/195: from bacteria
- G01N 2333/52: Assays involving cytokines
- G01N 2800/102: Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Y: ENZYMES

## Abstract

The present invention relates to the use of plasminogen/plasmin and its derivatives as agents for enhancing host defense against infection or other infectious diseases. The invention also relates to a method for screening of compounds which enhance host defense against infection by evaluating the host defense against bacterial arthritis and spontaneous otitis media in an animal model.

## Claims

### Claim 1

A method for the prophylaxis, prevention and/or treatment of infectious disease, which comprises administering a pharmaceutical composition comprising an effective amount of a compound selected from the group consisting of plasminogen, Lys-plasminogen, Glu-plasminogen, variants of plasminogen comprising one or more of the kringle domains and the proteolytic domain, mini-plasminogen, and kringle domains of plasminogen to a subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the infectious disease is a bacterial infectious disease or a viral infectious disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein the bacterial infectious disease is selected from the group consisting of otitis media and bacterial arthritis.

### Claim 4 (depends on 2)

The method of claim 2, wherein the bacterial infectious disease is selected from the group consisting of pneumonia, injuries in the respiratory organs caused by infections, and injuries in the joint tissues caused by infections.

### Claim 5 (depends on 2)

The method of claim 2, wherein the bacterial infectious disease is selected from the group consisting of gingivitis, periodontitis, and conjunctivitis.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises a combination of two or more of the compounds.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition further comprises at least one antibiotic agent.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antibiotic agent is selected from the group consisting of tetracyclines, amphenicols, beta-lactams, penicillins, sulphonamides, macrolides, lincosamides, streptogamins, streptomycins, quinolones and metronidazoles.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject is deficient in plasmin or plasminogen.

### Claim 11 (depends on 10)

The method of claim 10, wherein the deficiency is selected from the group consisting of congenital, acquired, and local.

### Claim 12 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered by a method selected from the group consisting of systemically, locally, topically, intravenously, intramuscularly, subcutaneously, via inhalation, intrathecally, via local injection, via intra-articular injection, and per rectally.

### Claim 13 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered in combination with a suitable polypeptide carrier or stabilizing agent.

### Claim 14 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered at a dose of 0.05 mg to about 10 mg.

### Claim 15 (depends on 1)

The method of claim 1, wherein the administration of the pharmaceutical composition is repeated at least once.

### Claim 16 (depends on 1)

The method of claim 1, wherein administering a pharmaceutical composition is performed by applying a wound dressing, comprising the pharmaceutical composition, to an infected area.

### Claim 17 (depends on 1)

The method of claim 1, wherein the method further comprises inducing an immune response against an infectious pathogen.

### Claim 18

A pharmaceutical composition for the prophylaxis, prevention and/or treatment of infectious disease comprising an effective amount of a compound selected from the group consisting of plasminogen, Lys-plasminogen, Glu-plasminogen, variants of plasminogen comprising one or more of the kringle domains and the proteolytic domain, mini-plasminogen, and kringle domains of plasminogen.

### Claim 19

A kit of parts for use in the prophylaxis, prevention and/or treatment of infectious disease comprising an effective amount of a compound selected from the group consisting of plasminogen, Lys-plasminogen, Glu-plasminogen, variants of plasminogen comprising one or more of the kringle domains and the proteolytic domain, mini-plasminogen, and kringle domains of plasminogen and at least one antibiotic or antimycotic agent, in separate containers.

### Claim 20 (depends on 9)

The method of claim 9, wherein the mammal is a human.

### Claim 21 (depends on 14)

The method of claim 14, wherein the pharmaceutical composition is administered at a dose from about 0.5 to about 5 mg.

### Claim 22 (depends on 15)

The method of claim 15, wherein the administration of the pharmaceutical composition is repeated at least every day.
